Thema: US30161Q1040
EXEL, US30161Q1040
new-york-stock-exchange-1708834_1920.jpg - Foto: THN
Exelixis stock trades at EUR 63.66 on Lang & Schwarz Friday
Exelixis stock was quoted on Lang & Schwarz in Friday evening trading. The biotechnology company develops and markets cancer treatments.
ad-hoc-news.de, heute 19:14 Uhr
EXEL, US30161Q1040
Bank of America keeps USD 41 target for Exelixis stock
Results arrive October 29, 2026. Exelixis stock costs EUR 58.53 on October 27, 2026, plus 2.47 percent versus the Xetra close.
ad-hoc-news.de, 27.10.26 18:50 Uhr
EXEL, US30161Q1040
RBC raises target for Exelixis stock from USD 45 to USD ...
Second-quarter revenue rose 10.60 percent to USD 628.69 million. Net profit reached USD 212.05 million, and Exelixis stock faces results October 29, 2026.
ad-hoc-news.de, 24.10.26 21:06 Uhr
EXEL, US30161Q1040
Exelixis stock: Citizens lifts Exelixis stock target to ...
Revenue reached USD 628.69 million in the second quarter. Exelixis stock costs EUR 58.21 on October 22, 2026 at 8:01 p.m. CEST against USD 65.00.
ad-hoc-news.de, 22.10.26 20:04 Uhr
EXEL, US30161Q1040
Citizens lifts target to USD 65 for Exelixis stock
Exelixis reported USD 628.69 million revenue in Q2 2026, up 10.60 percent. Exelixis stock costs EUR 56.84 on October 20, 2026.
ad-hoc-news.de, 20.10.26 20:49 Uhr
EXEL, US30161Q1040
Exelixis stock sits 1.83 percent below its 52-week high ...
2026 revenue guidance is USD 2.50-2.55 billion, issued August 5, 2026. Exelixis stock was last at EUR 55.36 on October 16, 2026.
ad-hoc-news.de, 17.10.26 21:18 Uhr
EXEL, US30161Q1040
Truist raises target for Exelixis stock to USD 54.00
Second-quarter revenue rose 10.60 percent to USD 628.69 million. Exelixis stock costs EUR 53.28 on October 8, 2026 after EUR 52.20.
ad-hoc-news.de, 08.10.26 19:49 Uhr
EXEL, US30161Q1040
Exelixis stock gets a higher Truist target at USD 54
Exelixis stock's Q2 revenue reached USD 628.69 million on August 5, 2026, up 10.6 percent year over year. EPS came in at USD 0.91 versus USD 0.85.
ad-hoc-news.de, 08.10.26 06:20 Uhr
EXEL, US30161Q1040
Exelixis delays cancer-drug review: what it means for Exelixis ...
Second-quarter revenue reached USD 628.69 million. For Exelixis stock, the FDA decision is now due March 3, 2027 for colorectal cancer.
ad-hoc-news.de, 07.10.26 01:15 Uhr
